Edward Pershing - 20 Feb 2026 Form 4 Insider Report for PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)

Role
CEO, Director
Signature
/s/ Edward Pershing
Issuer symbol
PVCT
Transactions as of
20 Feb 2026
Net transactions value
-$125,000
Form type
4
Filing time
23 Feb 2026, 14:05:49 UTC
Previous filing
23 Feb 2026
Next filing
27 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Pershing Edward CEO, Director 800 S. GAY STREET,, SUITE 1610, KNOXVILLE /s/ Edward Pershing 23 Feb 2026 0001689739

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PVCT 8% Unsecured Convertible Promissory Note Options Exercise $125,000 $1,245,000 20 Feb 2026 Series D-1 Convertible Preferred Stock 47,180 $2.86 Direct F3, F4
transaction PVCT Series D-1 Convertible Preferred Stock Options Exercise $0 +47,180 +1.8% $0.000000 2,660,987 20 Feb 2026 Common Stock 471,800 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").
F2 The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.
F3 The Reporting Person could have voluntarily elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "2025 Note") at any time while the 2025 Note was outstanding into shares of Series D-1 Convertible Preferred Stock at a price per share equal to $2.862. The outstanding principal and interest of the 2025 Note automatically converted into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the 2025 Note. The 2025 Note was issued pursuant to the Issuer's 2025 Financing.
F4 On February 20, 2026, the 2025 Note was converted into 47,180 shares of Series D-1 Preferred Stock.